Adrian Hargrave, CEO of SEEEN, explains how the new funds will accelerate customer growth Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksGlaxosmithkline Share News (GSK)

Share Price Information for Glaxosmithkline (GSK)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1,650.50
Bid: 1,652.00
Ask: 1,652.50
Change: 35.50 (2.20%)
Spread: 0.50 (0.03%)
Open: 1,631.00
High: 1,663.50
Low: 1,630.50
Prev. Close: 1,615.00
GSK Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

LONDON MARKET PRE-OPEN: Shares Seen Higher; Sky Hikes Dividend

Wed, 29th Jul 2015 06:34

LONDON (Alliance News) - London stocks are set to open higher Wednesday, following a flurry of UK company updates, with broadcaster Sky increasing its full year dividend as it posted a rise in pretax profit.

Sky posted a pretax profit of GBP1.52 billion for the year to end-June, up from GBP1.03 billion a year before, as revenue rose to GBP9.99 billion from GBP7.45 billion. The reported results include Sky Italia and Sky Deutschland following their acquisition in November. On an adjusted basis, including the results of the Italian and German business for the full year and at constant currency, pretax profit rose to GBP1.20 billion, up from GBP1.13 billion a year before, on revenue of GBP11.28 billion, up from GBP10.78 billion.

The company proposed a final dividend of 20.5 pence, which takes its total dividend for the year to 32.8 pence, up from 32.0 pence a year before.

There also have been results from Barclays, Taylor Wimpey and Capita, among others. GlaxoSmithKline is expected to release its second-quarter results at 1200 BST.

In its first set of results since the board sacked Antony Jenkins as chief executive earlier this month, Barclays reported an increase in second-quarter net profit, and revealed plans to intensify the scaling down of its non-core assets.

Net profit increased to GBP1.15 billion in the quarter ended June 30, compared with GBP161 million in the corresponding period the prior year. Adjusted pretax profit, a closely watched measure of the bank's performance, increased to GBP1.85 billion in the quarter, up from GBP1.66 billion year-on-year, ahead of the GBP1.75 billion forecast by analysts.

Barclays's interim dividend remains at 2.0 pence per share.

IG says futures indicate the FTSE 100 to open 28 points higher at 6,583.30. The index closed up 0.8% at 6,555.28, taking back about half of Monday's losses.

Later in the day, attention will shift to the US Federal Open Market Committee two-day meeting, with its interest rate announcement due at 1900 BST. Ahead of the decision, Wall Street ended higher Tuesday. The DJIA closed up 1.1%, the S&P 500 ended up 1.2% and the Nasdaq Composite finished up 1.0%.

The US Federal Reserve is widely expected to leave US interest rates unchanged at the meeting. However, investors will pay attention to the accompanying monetary policy statement, after a recent hawkish speech and Congressional testimony by Fed Chair Janet Yellen intensified expectations that the bank would hike rates later this year.

Many analysts still expect the Fed to raise US interest rates at its next meeting in September and will be closely scrutinizing the statement for any hints about the timing of the first US rate hike in nine years.

Lloyds Bank highlights that the bigger question is whether the Fed wants to send a clearer signal that it intends to hike at its next meeting in September. The bank notes that at the start of the previous interest rate tightening cycle in 2004, the statement was changed to read "the Committee believes that policy accommodation can be removed at a pace that is likely to be measured".

"A similar change in language this time would strongly suggest that the FOMC intends to hike at the next meeting, unless the economic data take a decisive turn for the worse," says Lloyds.

CMC Markets chief market analyst Michael Hewson says, "a lot can happen, not only data wise between now and [when a rate hike arrives], but there also remains a great deal of uncertainty between now and then with respect to the China growth story, as well as a successful outcome to what is currently going in Greece."

Greece's government launched negotiations Tuesday on a new multi-billion-euro bailout programme, insisting that it has taken all the measures agreed with creditors for reaching a deal. Representatives of Greece's creditors started talks at a technical level, visiting Greece's General Accounting Office and the Bank of Greece, a Greek finance ministry official said Tuesday.

The same official said "technical groups are expected to complete their work by Friday 31 July" adding that no further meetings are expected during the weekend, "unless otherwise specified".

According to the same official, mission chiefs of the institutions overseeing the bailout - the European Commission, the European Central Bank, the International Monetary Fund as well as the European Stability Mechanism are expected to arrive in Athens on Wednesday. The official said both sides aim to complete the deal "as soon as possible."

The Greek Parliament passed two reform packages that were part of the conditions agreed on July 13 in Brussels to secure up to EUR86 billion in new financing. The major sticking point is whether Greece will have to pass another round of difficult and politically divisive austerity measures, such as pension reforms, before negotiations conclude.

In Asia on Wednesday, the Japanese Nikkei 225 closed down 0.2%. In China, stocks are mixed, with the Hang Seng up 0.2%, and the Shanghai Composite down 0.2%.

Alongside the Fed interest rate decision, in the economic calendar are UK consumer credit and mortgage approvals data due at 0930 BST. In the US, pending home sales are due at 1500 BST, while EIA Crude Oil stocks are at 1530 BST.

By Daniel Ruiz; danielruiz@alliancenews.com

Copyright 2015 Alliance News Limited. All Rights Reserved.

More News
1 Nov 2023 07:27

GSK hikes guidance after strong third quarter

(Sharecast News) - GSK announced a robust third quarter on Wednesday, prompting an upgrade to its full-year guidance.

Read more
30 Oct 2023 09:01

IN BRIEF: GSK says Jemperli meets endpoint in endometrial cancer trial

GSK PLC - Brentford, west London-based pharmaceutical maker - Jemperli, whose generic name is dostarlimab, meets endpoint of overall survival in phase III Ruby trial on adult patients with primary advanced or recurrent endometrial cancer. Jemperli, combined with standard-of-care chemotherapy, followed by dostarlimab, demonstrated a "statistically significant and clinically meaningful benefit" to the patients in the trial.

Read more
30 Oct 2023 07:06

GSK's Jemperli sees success in endometrial cancer trial

(Sharecast News) - GSK reported encouraging outcomes from part one of the 'RUBY' phase three trial evaluating the efficacy of 'Jemperli', or dostarlimab, with standard chemotherapy for treating adult patients with advanced or recurrent endometrial cancer on Monday.

Read more
26 Oct 2023 09:19

TOP NEWS: GSK subsidiary ViiV receives HIV drug approval in China

(Alliance News) - GSK PLC on Thursday said its subsidiary ViiV Healthcare has received marketing authorisation in China for its cabotegravir treatment, marketed as Vocabria.

Read more
26 Oct 2023 07:02

GSK HIV injection regimen gets approval in China

(Sharecast News) - GSK announced on Thursday that its majority-owned HIV specialist subsidiary ViiV has received approval from the National Medical Products Administration (NMPA) of China for an injection regimen.

Read more
25 Oct 2023 16:01

UK earnings, trading statements calendar - next 7 days

Thursday 26 October 
Bank of Ireland Group PLCTrading Statement
Bloomsbury Publishing PLCHalf Year Results
Botswana Diamonds PLCTrading Statement
C&C Group PLCHalf Year Results
e-Therapeutics PLCHalf Year Results
Financials Acquisition CorpTrading Statement
GCP Infrastructure Investments LtdTrading Statement
HarbourVest Global Private Equity LtdHalf Year Results
Hummingbird Resources PLCTrading Statement
Hunting PLCTrading Statement
Inchcape PLCTrading Statement
International Personal Finance PLCTrading Statement
PPHE Hotel Group LtdTrading Statement
Renishaw PLCTrading Statement
Standard Chartered PLCQ3 Results
Unilever PLCTrading Statement
WPP PLCTrading Statement
Friday 27 October 
International Consolidated Airlines Group SAQ3 Results
NatWest Group PLCQ3 Results
Monday 30 October 
Airtel Africa PLCHalf Year Results
Computacenter PLCTrading Statement
Glencore PLCTrading Statement
HSBC Holdings PLCQ3 Results
Lok'n Store Group PLCFull Year Results
Pearson PLCTrading Statement
Tuesday 31 October 
BP PLCQ3 Results
Coca-Cola HBC AGTrading Statement
Elementis PLCTrading Statement
essensys PLCFull Year Results
Georgia Capital PLCQ3 Results
Grit Real Estate Income Group LtdFull Year Results
RHI Magnesita NVTrading Statement
Spectris PLCQ3 Results
TP ICAP Group PLCTrading Statement
UP Global Sourcing Holdings PLCFull Year Results
Wednesday 1 November 
Asos PLCFull Year Results
Aston Martin Lagonda Global Holdings PLCQ3 Results
Beximco Pharmaceuticals LtdFull Year Results
GSK PLCQ3 Results
Next PLCTrading Statement
Smurfit Kappa Group PLCTrading Statement
Weir Group PLCTrading Statement
  
Copyright 2023 Alliance News Ltd. All Rights Reserved.

Read more
25 Oct 2023 09:35

GSK says RSV jab shows promising response in adults aged 50 to 59

(Alliance News) - GSK PLC on Wednesday said a trial found its respiratory syncytial virus vaccine Arexy delivered an immune response in adults aged 50 to 59.

Read more
25 Oct 2023 07:27

GSK hails success in US RSV vaccine trial

(Sharecast News) - Pharma giant GSK has announced positive preliminary results from a trial of its Arexvy vaccine to treatment respiratory syncytial virus (RSV) disease for a younger patient population in the US.

Read more
16 Oct 2023 08:09

TOP NEWS: GSK receives positive EU opinion on Jemperli for cancer

(Alliance News) - GSK PLC on Monday said its monoclonal antibody Jemperli is closer to becoming the first new frontline treatment option in the EU in decades for a certain form of endometrial cancer.

Read more
16 Oct 2023 07:44

LONDON BRIEFING: Hipgnosis pulls interim dividend on lower royalties

(Alliance News) - The FTSE 100 is likely to open higher on Monday, benefitting from higher oil and gas prices, while fears of escalating regional conflict in the Middle East damp risk sentiment elsewhere.

Read more
16 Oct 2023 07:16

GSK nears green light for Jemperli usage in Europe

(Sharecast News) - Pharma giant GSK has announced that European experts recommended the approval of its Jerperli drug for the treatment of a specific type of endometrial cancer - paving the way for marketing authorisation by the continent's regulatory body.

Read more
11 Oct 2023 11:51

GSK settles California Zantac lawsuit

(Sharecast News) - GSK has agreed to settle another lawsuit concerning its discontinued heartburn treatment Zantac, the drugs giant confirmed on Wednesday.

Read more
11 Oct 2023 09:17

LONDON BROKER RATINGS: JPMorgan raises Croda; Berenberg cuts Atalaya

(Alliance News) - The following London-listed shares received analyst recommendations Wednesday morning:

Read more
11 Oct 2023 08:51

LONDON MARKET OPEN: FTSE 100 higher; Travis Perkins warns on profit

(Alliance News) - Stock prices in London opened largely higher on Wednesday as market mood remained resilient, despite the continuing conflict in the Middle East, amid a softening of rhetoric from the US central bank.

Read more
11 Oct 2023 08:36

TOP NEWS: GSK reaches settlement for Zantac litigation in California

(Alliance News) - GSK PLC on Wednesday said that it has reached a confidential settlement in the Cantlay/Harper case, which alleged that the firm's heartburn medication can cause cancer.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.